Author Correction: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity

Douglas W McMillin^{1

2

3}, Jake Delmore^{1

2

3}, Ellen Weisberg^{2

3}, Joseph M Negri^{1

2

3}, Corey D Geer^{1

2

3}, Steffen Klippel^{1

2

3}, Nicholas Mitsiades^{1

2}, Robert L Schlossman^{1

2

3}, Nikhil C Munshi^{1

2

3

4}, Andrew L Kung⁵, James D Griffin^{2

3}, Paul G Richardson^{1

2

3}, Kenneth C Anderson^{1

2

3}, Constantine S Mitsiades^{6

7

8}

Affiliations

¹ Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
² Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA.
³ Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
⁴ Boston VA Healthcare System, Boston, Massachusetts, USA.
⁵ Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
⁶ Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. constantine_mitsiades@dfci.harvard.edu.
⁷ Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA. constantine_mitsiades@dfci.harvard.edu.
⁸ Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. constantine_mitsiades@dfci.harvard.edu.

PMID: 38355975
DOI: 10.1038/s41591-024-02847-5

Published Erratum

Author Correction: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity

Douglas W McMillin et al. Nat Med. 2024 Apr.

. 2024 Apr;30(4):1214.

doi: 10.1038/s41591-024-02847-5.

Authors

Affiliations

¹ Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
² Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA.
³ Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
⁴ Boston VA Healthcare System, Boston, Massachusetts, USA.
⁵ Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
⁶ Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. constantine_mitsiades@dfci.harvard.edu.
⁷ Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA. constantine_mitsiades@dfci.harvard.edu.
⁸ Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. constantine_mitsiades@dfci.harvard.edu.

PMID: 38355975
DOI: 10.1038/s41591-024-02847-5

No abstract available

PubMed Disclaimer

Erratum for

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.
McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S, Mitsiades N, Schlossman RL, Munshi NC, Kung AL, Griffin JD, Richardson PG, Anderson KC, Mitsiades CS. McMillin DW, et al. Nat Med. 2010 Apr;16(4):483-9. doi: 10.1038/nm.2112. Epub 2010 Mar 14. Nat Med. 2010. PMID: 20228816 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Author Correction: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity

Affiliations

Author Correction: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources